Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#2 Ontology Gas Ontology Gas +17.76%
#3 GoPlus Security GoPlus Security +9.80%
#4 Janction Janction +9.64%
#5 DMT-NAT DMT-NAT +7.80%
#6 Provenance Blockchain Provenance Blockchain +6.63%
#7 B3 (Base) B3 (Base) +6.09%
#8 Ontology Ontology +6.08%
#9 Status Status +5.87%
#10 Everything Everything +5.64%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
設定
言語
日本
通貨
USD
テーマ
PJSC Pharmsynthez PJSC Pharmsynthez

PJSC Pharmsynthez

LIFE
株式のランク #34086
PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation,... PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.
株価
$0.02082992
最終同期: 2026-08-14
時価総額
$6.27M
変化（1日）
-3.31%
変化（1年）
-51.62%
国
RU
取引 PJSC Pharmsynthez (LIFE)

カテゴリー

Healthcare
PJSC Pharmsynthez（LIFE）のP/S比率
2026 時点のP/S比率 TTM: 0
PJSC Pharmsynthez の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
PJSC Pharmsynthez の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
年 P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE